Context Therapeutics Stock Current Liabilities

CNTX Stock  USD 1.36  0.03  2.16%   
Context Therapeutics fundamentals help investors to digest information that contributes to Context Therapeutics' financial success or failures. It also enables traders to predict the movement of Context Stock. The fundamental analysis module provides a way to measure Context Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Context Therapeutics stock.
Total Current Liabilities is likely to rise to about 6.2 M in 2024, whereas Non Current Liabilities Total is likely to drop 0.00 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Context Therapeutics Company Current Liabilities Analysis

Context Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Context Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for Context Therapeutics is extremely important. It helps to project a fair market value of Context Stock properly, considering its historical fundamentals such as Current Liabilities. Since Context Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Context Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Context Therapeutics' interrelated accounts and indicators.
0.98-0.07-0.51-0.390.040.08-0.690.32-0.550.97-0.60.080.57-0.02-0.320.460.260.33
0.980.06-0.54-0.440.04-0.06-0.830.27-0.610.97-0.73-0.060.710.0-0.440.550.410.44
-0.070.060.48-0.02-0.76-0.6-0.33-0.880.380.14-0.03-0.60.5-0.7-0.880.760.890.88
-0.51-0.540.480.31-0.590.180.45-0.770.7-0.390.620.18-0.32-0.56-0.360.250.180.35
-0.39-0.44-0.020.31-0.32-0.010.44-0.260.28-0.370.35-0.01-0.41-0.370.2-0.42-0.17-0.22
0.040.04-0.76-0.59-0.320.36-0.080.91-0.64-0.17-0.360.36-0.070.990.61-0.46-0.58-0.6
0.08-0.06-0.60.18-0.010.360.270.39-0.11-0.080.211.0-0.320.270.35-0.25-0.49-0.35
-0.69-0.83-0.330.450.44-0.080.27-0.120.68-0.70.90.27-0.94-0.070.62-0.64-0.67-0.62
0.320.27-0.88-0.77-0.260.910.39-0.12-0.710.1-0.40.39-0.070.860.66-0.5-0.63-0.66
-0.55-0.610.380.70.28-0.64-0.110.68-0.71-0.410.91-0.11-0.44-0.61-0.050.040.060.05
0.970.970.14-0.39-0.37-0.17-0.08-0.70.1-0.41-0.56-0.080.61-0.2-0.490.60.420.5
-0.6-0.73-0.030.620.35-0.360.210.9-0.40.91-0.560.21-0.72-0.360.32-0.3-0.34-0.32
0.08-0.06-0.60.18-0.010.361.00.270.39-0.11-0.080.21-0.320.270.35-0.25-0.49-0.35
0.570.710.5-0.32-0.41-0.07-0.32-0.94-0.07-0.440.61-0.72-0.32-0.08-0.70.730.820.7
-0.020.0-0.7-0.56-0.370.990.27-0.070.86-0.61-0.2-0.360.27-0.080.57-0.43-0.55-0.57
-0.32-0.44-0.88-0.360.20.610.350.620.66-0.05-0.490.320.35-0.70.57-0.94-0.92-1.0
0.460.550.760.25-0.42-0.46-0.25-0.64-0.50.040.6-0.3-0.250.73-0.43-0.940.860.95
0.260.410.890.18-0.17-0.58-0.49-0.67-0.630.060.42-0.34-0.490.82-0.55-0.920.860.92
0.330.440.880.35-0.22-0.6-0.35-0.62-0.660.050.5-0.32-0.350.7-0.57-1.00.950.92
Click cells to compare fundamentals

Context Current Liabilities Historical Pattern

Today, most investors in Context Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Context Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Context Therapeutics current liabilities as a starting point in their analysis.
   Context Therapeutics Current Liabilities   
       Timeline  
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition

Context Total Current Liabilities

Total Current Liabilities

6.17 Million

At this time, Context Therapeutics' Total Current Liabilities is fairly stable compared to the past year.
In accordance with the recently published financial statements, Context Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.

Context Current Liabilities Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Context Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Context Therapeutics could also be used in its relative valuation, which is a method of valuing Context Therapeutics by comparing valuation metrics of similar companies.
Context Therapeutics is currently under evaluation in current liabilities category among its peers.

Context Fundamentals

About Context Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Context Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.